AI-generated analysis. Always verify with the original filing.
Calidi Biotherapeutics reported its fourth quarter and full-year 2025 financial results, including a net loss of $4.1 million for Q4 2025 and $25.6 million for the full year. The company also announced recent operational developments, including partnerships to advance its lead asset CLD-401 and a capital raise of $6.5 million.
Event Type
Disclosure
Mandatory
Variant
8-K
is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
disclosure, including Exhibit 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the
Financial Statements and Exhibits. (d) Exhibits Exhibit Exhibit Description 99.1 Press Release dated March 27, 2026 104 Cover Page Interactive Data File (embedd
| Metric | Value | Basis |
|---|---|---|
| Net Loss Attributable to Common Stockholders | $-4.10 | |
| Diluted EPS | $-0.57 | |
| Research and Development Expenses | $2.40 | |
| General and Administrative Expenses | $2.10 |